Upadacitinib Can Significantly Improve Clinical Outcomes in

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Related Keywords

San Diego , California , United States , American , Jonathan Silverberg , Clinical Research , Health Sciences , American Academy Of Dermatology , Path Testing , George Washington University School , Eczema Area , Severity Index , Investigator Global Assessment , Worst Pruritus Numerical Rating Scale , Patient Oriented Eczema Measure , Hospital Anxiety , Depression Scale , Dermatology Life Quality , Annual Meeting , With Upadacitinib Increases , Results From Phase , Atopic Dermatitis ,